These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 19797820)
1. Human microdosing; a boon or a bane? Seth SD; Kumar NK; Dua P Indian J Med Res; 2009 Aug; 130(2):202-4. PubMed ID: 19797820 [No Abstract] [Full Text] [Related]
2. Microdosing Studies in Children: A US Regulatory Perspective. Roth-Cline M; Nelson RM Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312 [TBL] [Abstract][Full Text] [Related]
3. Phase I trials: from traditional to newer approaches part II. Macaluso M; Krams M; Preskorn SH J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829 [TBL] [Abstract][Full Text] [Related]
4. The future of biomarkers. Aruoma OI; Bahorun T Toxicology; 2010 Dec; 278(2):161-4. PubMed ID: 20888386 [No Abstract] [Full Text] [Related]
5. Ethical, legal, and social implications (ELSI) of microdose clinical trials. Kurihara C Adv Drug Deliv Rev; 2011 Jun; 63(7):503-10. PubMed ID: 21251940 [TBL] [Abstract][Full Text] [Related]
6. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs. Kefalas CH; Ciociola AA Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264 [No Abstract] [Full Text] [Related]
8. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
9. Less is more: the human microdosing concept. Garner RC Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185 [No Abstract] [Full Text] [Related]
11. [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years]. Glazer A; Hedenmalm K Lakartidningen; 2008 Sep 10-16; 105(37):2482-4. PubMed ID: 19006863 [No Abstract] [Full Text] [Related]
12. Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. Romero K; Corrigan B; Tornoe CW; Gobburu JV; Danhof M; Gillespie WR; Gastonguay MR; Meibohm B; Derendorf H J Clin Pharmacol; 2010 Sep; 50(9 Suppl):9S-19S. PubMed ID: 20881213 [No Abstract] [Full Text] [Related]
13. Pediatric microdose and microtracer studies using 14C in Europe. Turner MA; Mooij MG; Vaes WH; Windhorst AD; Hendrikse NH; Knibbe CA; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Tibboel D; Park BK; de Wildt SN Clin Pharmacol Ther; 2015 Sep; 98(3):234-7. PubMed ID: 26095095 [TBL] [Abstract][Full Text] [Related]
14. In brief: Non-inferiority trials. Med Lett Drugs Ther; 2011 Jan; 53(1355):1. PubMed ID: 21212743 [No Abstract] [Full Text] [Related]
15. Paediatric clinical trials: redressing the imbalance. Schreiner MS Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794 [No Abstract] [Full Text] [Related]
16. A taste of new medicine. Nat Med; 2006 May; 12(5):481. PubMed ID: 16675969 [No Abstract] [Full Text] [Related]
17. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues. Rowland SS; Mayner RL; Barker L Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026 [TBL] [Abstract][Full Text] [Related]
18. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Rosenberger WF; Manukyan Z Stat Med; 2009 Dec; 28(30):3751-3; discussion 3759-60. PubMed ID: 19967756 [No Abstract] [Full Text] [Related]